XLV
The Health Care Select Sector SPDR Fund
Select Sector SPDR® holding S&P 500 stocks in the Health Care sector. Component industries include Health Care Equipment & Services; and Pharmaceutical & Biotechnology. The fund seeks investment results that, before expenses, generally correspond to the price and yield performance of the benchmark index.
US
EQUITY
Passive
MANAGEMENT STYLE
39.9 B
ASSETS UNDER MGMT
8 bp
EXPENSES
Fund Basics
| Fund sponsor | State Street Global Advisors |
| Category | US |
| Asset class | Equity |
| Website | link... |
| Inception date | Dec 16, 1998 |
| Assets (mns) | $39,898 |
| Expense ratio | 8 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Quarterly |
| Taxation | 1099 |
| Stock selection | Committee |
| Weighting | Market Cap |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 15.2 % |
| JOHNSON & JOHNSON | 8.9 % |
| ABBVIE INC | 7.2 % |
| UNITEDHEALTH GROUP INC | 5.3 % |
| MERCK & CO. INC. | 4.7 % |
| ABBOTT LABORATORIES | 3.9 % |
| THERMO FISHER SCIENTIFIC INC | 3.9 % |
| INTUITIVE SURGICAL INC | 3.6 % |
| AMGEN INC | 3.1 % |
| GILEAD SCIENCES INC | 2.7 % |
Constituent Breakdown
| Number of holdings | 60 |
| Herfindahl-Hirschman Index | 510 |
| Wgt avg mkt cap (mns) | $311,398 |
| Large cap (>$10bn) | 98.8% |
| Mid cap ($2-10bn) | 1.0% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 99.8% |
| Emerging mkts. | 0.0% |
Country Exposure
 |
UNITED STATES | 97.1 % |
 |
IRELAND | 2.6 % |
Historical Performance
Standardized Performance (as of 12/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 12.5% | 12.5% | 6.5% | 4.4% | 6.4% | 8.0% | 8.2% | 7.0% |
| Dividend Yield | 2.0% | 2.0% | 1.8% | 1.7% | 1.7% | 1.8% | 1.9% | 1.6% |
| Total Returns | 14.5% | 14.5% | 8.3% | 6.2% | 8.1% | 9.8% | 10.1% | 8.6% | Ann. Volatility | 17.3% | 17.3% | 14.4% | 13.5% | 14.5% | 16.6% | 16.9% | 17.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.49 | 30% |
| MSCI EAFE | 0.64 | 37% |
| MSCI Emg Mkts | 0.41 | 17% |
Liquidity Measures
| Avg. volume (000) | 9,905 |
| ADV traded (mns) | $1,540 |
| Turnover | 3.9% |
| Avg. Bid/Ask (% of price) | 0.01% |
Technical Indicators
| 30d moving avg. (EMA) | $153.13 |
| Relative strength (RSI) | 60 |
| MACD/Signal | 1.24/1.32 |
| Bollinger Bands (Upper/Lower) | $157.35/$150.27 |
| Short interest (% of AUM) | 6.4% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XLV |
Expenses vs. XLV |
ALTAR Score™ vs. XLV |
|---|---|---|---|---|
| FHLC | Fidelity MSCI Health Care Index ETF | 84.9% | +0 bp | +5.1% |
| VHT | Vanguard Health Care ETF | 81.6% | +1 bp | +4.9% |
| HRTS | Tema Heart & Health ETF | 56.4% | +67 bp | +2.0% |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 53.2% | +32 bp | +6.6% |
| MEDX | Horizon Kinetics Medical ETF | 41.1% | +77 bp | +1.3% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 39.8% | +52 bp | +7.0% |
| LVDS | JPMorgan Fundamental Data Science Large Value ETF | 38.9% | +41 bp | +5.8% |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 38.7% | +67 bp | +2.3% |
| PPH | VanEck Pharmaceutical ETF | 37.2% | +28 bp | +6.4% |
| MEDI | Harbor Health Care ETF | 37.1% | +72 bp | -1.5% |
Risk and Returns: XLV vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2024 | 2025 | 2026 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 1/2/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
OVERWEIGHT
Above average appreciation potential. A rating of OVERWEIGHT is assigned to ETFs with ALTAR Scores in the 4th quintile (ranking higher than 60%-80%) of their category. Typically, funds in this category consist of stocks trading at attractive valuations and/or having above-average fundamentals.
ALTAR Score™
XLV
6.1%
Cat. Avg
5.0%
ALTAR Score™ Calculation
Category Overview
There are 1029 funds in the US Equity category, with an average ALTAR Score™
of 5.0% and a standard deviation of
2.3%. XLV's ALTAR Score™ is approximately
0.5 standard deviations
above
the category average. This places XLV in the 68th percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
XLVSELL
U/W
HOLD
O/W
BUY